J&J to purchase Ambrx Biopharma for $2 billion in all-cash deal
HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..
Drugs
Health
Pharma